Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.16 (
calcineurin
)
17,112
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
TRIP-Br proteins are a novel family of transcriptional coregulators involved in E2F-mediated cell cycle progression. Three of the four mammalian members of TRIP-Br family, including
TRIP-Br1
, are known oncogenes. We now report the identification of the Balpha regulatory subunit of serine/threonine protein phosphatase 2A (
PP2A
) as a novel
TRIP-Br1
interactor, based on an affinity binding assay coupled with mass spectrometry. A GST-
TRIP-Br1
fusion protein associates with catalytically active
PP2A
-ABalphaC holoenzyme in vitro. Coimmunoprecipitation confirms this association in vivo. Immunofluorescence staining with a monoclonal antibody against
TRIP-Br1
reveals that endogenous
TRIP-Br1
and
PP2A
-Balpha colocalize mainly in the cytoplasm. Consistently, immunoprecipitation followed by immunodetection with anti-phosphoserine antibody suggest that
TRIP-Br1
exists in a serine-phosphorylated form. Inhibition of
PP2A
activity by okadaic acid or transcriptional silencing of the
PP2A
catalytic subunit by small interfering RNA results in downregulation of total
TRIP-Br1
protein levels but upregulation of serine-phosphorylated
TRIP-Br1
. Overexpression of
PP2A
catalytic subunit increases
TRIP-Br1
protein levels and
TRIP-Br1
co-activated E2F1/DP1 transcription. Our data support a model in which association between
PP2A
-ABalphaC holoenzyme and
TRIP-Br1
in vivo in mammalian cells represents a novel mechanism for regulating the level of
TRIP-Br1
protooncoprotein.
...
PMID:Identification of PP2A as a novel interactor and regulator of TRIP-Br1. 1894 Feb 48